Esperion Therapeutics Blocks Dr. Reddy's Generic Version of Cholesterol Drugs Until 2040

Dow Jones

Oct 03

By Adriano Marchese

Dr. Reddy's Laboratories won't market a generic version of Esperion Therapeutics' cholesterol drugs after a reaching a settlement.

Esperion Therapeutics, a pharmaceutical company, said Friday that it has settled with India-based pharmaceutical company Dr. Reddy's which was seeking approval to market its own generic versions of its Nexletol and Nexlizet.

Nexletol and Nexlizet are prescription medications used to lower LDL cholesterol, known as the bad cholesterol, and reduce the risk of heart-related issues in adults.

Dr. Reddy's had made an abbreviated new drug application for its generic version of the drugs, but following the settlement, Dr. Reddy's Laboratories has agreed not to market a generic version of either in the U.S. before 2040.

Dr. Reddy's wasn't readily available for comment.

Earlier this year, Esperion said it had reached settlement agreements with a number of other pharmaceuticals regarding generic versions of Nexletol.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

October 03, 2025 08:42 ET (12:42 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2572507271"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2572507271\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2572507271?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-03 20:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572507271","market":"hk","top_or_hot":-1,"title":"Esperion Therapeutics Blocks Dr. Reddy's Generic Version of Cholesterol Drugs Until 2040","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Dr. Reddy's Laboratories won't market a generic version of Esperion <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' cholesterol drugs after a reaching a settlement. \n</p>\n<p>\n  Esperion Therapeutics, a pharmaceutical company, said Friday that it has settled with India-based pharmaceutical company Dr. Reddy's which was seeking approval to market its own generic versions of its Nexletol and Nexlizet. \n</p>\n<p>\n  Nexletol and Nexlizet are prescription medications used to lower LDL cholesterol, known as the bad cholesterol, and reduce the risk of heart-related issues in adults. \n</p>\n<p>\n  Dr. Reddy's had made an abbreviated new drug application for its generic version of the drugs, but following the settlement, Dr. Reddy's Laboratories has agreed not to market a generic version of either in the U.S. before 2040. \n</p>\n<p>\n  Dr. Reddy's wasn't readily available for comment. \n</p>\n<p>\n  Earlier this year, Esperion said it had reached settlement agreements with a number of other pharmaceuticals regarding generic versions of Nexletol. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 03, 2025 08:42 ET (12:42 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Esperion Therapeutics Blocks Dr. Reddy's Generic Version of Cholesterol Drugs Until 2040</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEsperion Therapeutics Blocks Dr. Reddy's Generic Version of Cholesterol Drugs Until 2040\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-03 20:42</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Dr. Reddy's Laboratories won't market a generic version of Esperion <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' cholesterol drugs after a reaching a settlement. \n</p>\n<p>\n  Esperion Therapeutics, a pharmaceutical company, said Friday that it has settled with India-based pharmaceutical company Dr. Reddy's which was seeking approval to market its own generic versions of its Nexletol and Nexlizet. \n</p>\n<p>\n  Nexletol and Nexlizet are prescription medications used to lower LDL cholesterol, known as the bad cholesterol, and reduce the risk of heart-related issues in adults. \n</p>\n<p>\n  Dr. Reddy's had made an abbreviated new drug application for its generic version of the drugs, but following the settlement, Dr. Reddy's Laboratories has agreed not to market a generic version of either in the U.S. before 2040. \n</p>\n<p>\n  Dr. Reddy's wasn't readily available for comment. \n</p>\n<p>\n  Earlier this year, Esperion said it had reached settlement agreements with a number of other pharmaceuticals regarding generic versions of Nexletol. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 03, 2025 08:42 ET (12:42 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4523","symbol_name":"印度概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2572507271","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2572507271","pubTimestamp":1759495320,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Dr. Reddy's Laboratories won't market a generic version of Esperion Therapeutics' cholesterol drugs after a reaching a settlement.Esperion Therapeutics, a pharmaceutical company, said Friday that it has settled with India-based pharmaceutical company Dr. Reddy's which was seeking approval to market its own generic versions of its Nexletol and Nexlizet.Nexletol and Nexlizet are prescription medications used to lower LDL cholesterol, known as the bad cholesterol, and reduce the risk of heart-related issues in adults.Dr. Reddy's had made an abbreviated new drug application for its generic version of the drugs, but following the settlement, Dr. Reddy's Laboratories has agreed not to market a generic version of either in the U.S. before 2040.Earlier this year, Esperion said it had reached settlement agreements with a number of other pharmaceuticals regarding generic versions of Nexletol.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4523":"印度概念","LU0348744763.USD":"ALLIANZ ASIA PACIFIC INCOME \"A\" (USD) INC","BK4557":"大麻股","ESPR":"Esperion Therapeutics Inc.","BK4532":"文艺复兴科技持仓","BK4596":"哈里斯概念","RDY":"如瑞迪博士","BK4007":"制药"},"translate_title":"Esperion Therapeutics在2040年之前阻止Reddy博士的胆固醇药物仿制药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ESPR":1.5,"RDY":0.9},"content_text":"By Adriano Marchese \n\n\n \n\n\n  Dr. Reddy's Laboratories won't market a generic version of Esperion Therapeutics' cholesterol drugs after a reaching a settlement. \n\n\n  Esperion Therapeutics, a pharmaceutical company, said Friday that it has settled with India-based pharmaceutical company Dr. Reddy's which was seeking approval to market its own generic versions of its Nexletol and Nexlizet. \n\n\n  Nexletol and Nexlizet are prescription medications used to lower LDL cholesterol, known as the bad cholesterol, and reduce the risk of heart-related issues in adults. \n\n\n  Dr. Reddy's had made an abbreviated new drug application for its generic version of the drugs, but following the settlement, Dr. Reddy's Laboratories has agreed not to market a generic version of either in the U.S. before 2040. \n\n\n  Dr. Reddy's wasn't readily available for comment. \n\n\n  Earlier this year, Esperion said it had reached settlement agreements with a number of other pharmaceuticals regarding generic versions of Nexletol. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 03, 2025 08:42 ET (12:42 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}